NURS 6521 Advanced Pharmacology
Midterm Comprehensive Examination
2026/2027 | Verified Questions
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles and Pharmacokinetics
Question 1. A patient with hepatic impairment is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic principle most
accurately guides dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30
mL/min
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral
bioavailability of high-extraction drugs. Therefore the dose must be decreased to
avoid toxicity. This principle is foundational in advanced pharmacokinetics for
nurse prescribers.
Question 2. Which parameter best predicts the time required for a drug to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Rationale: Steady state is reached after approximately four to five half-lives
regardless of dose or infusion rate. Elimination half-life is therefore the primary
determinant of time to steady state.
Question 3. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
,D. Decreased free fraction because hepatic synthesis of albumin increases
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of
highly protein-bound drugs. The unbound concentration drives pharmacologic
effect and toxicity risk, requiring careful monitoring.
Question 4. Which cytochrome P450 enzyme is responsible for the majority of
clinically significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
Rationale: CYP3A4 is involved in the metabolism of more than 50% of all
prescription medications. It is highly susceptible to inhibition and induction,
making it the most common source of clinically significant drug interactions.
Question 5. A patient is prescribed a drug with a narrow therapeutic index. Which
monitoring strategy is most appropriate?
A. Routine monitoring of serum drug levels to ensure they remain within the
therapeutic range
B. Administering the drug only when symptoms are severe
C. Using the standard dose without monitoring, as it is usually safe
D. Monitoring only for adverse effects, not serum levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Routine serum level monitoring is essential to prevent
toxicity or subtherapeutic failure.
Question 6. What is the primary purpose of a loading dose?
A. To maintain steady-state plasma concentrations
B. To rapidly achieve therapeutic plasma concentrations
C. To reduce the risk of adverse effects
D. To prolong the elimination half-life of the drug
Rationale: A loading dose is administered to rapidly reach the therapeutic range,
bypassing the time it would take to reach steady state through maintenance dosing
alone.
Question 7. Which of the following describes a drug that is a competitive
antagonist?
A. It binds to the receptor and activates it.
B. It binds to the receptor and blocks the action of an agonist, but can be
,overcome by increasing the agonist concentration.
C. It binds irreversibly to the receptor and permanently inactivates it.
D. It binds to an allosteric site and enhances the agonist effect.
Rationale: A competitive antagonist competes with the agonist for the same
binding site. Its effects can be overcome by increasing the concentration of the
agonist.
Question 8. A patient with renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What is the most appropriate initial dose
adjustment?
A. Decrease the dose or increase the dosing interval.
B. Increase the dose to compensate for loss of renal function.
C. Maintain the usual dose but monitor closely.
D. Administer a loading dose only.
Rationale: Renal impairment reduces the clearance of drugs excreted unchanged
by the kidneys, leading to accumulation and toxicity. Dose reduction or interval
extension is necessary.
Question 9. What is the definition of bioavailability?
A. The amount of drug metabolized by the liver
B. The fraction of an administered dose that reaches the systemic circulation
unchanged
C. The volume of plasma cleared of drug per unit time
D. The time it takes for half of the drug to be eliminated
Rationale: Bioavailability (F) represents the extent and rate at which the active
drug enters systemic circulation, which is 100% for intravenous administration but
less for oral routes due to incomplete absorption and first-pass metabolism.
Question 10. Which of the following is an example of a drug that undergoes
extensive first-pass metabolism?
A. Diazepam
B. Lorazepam
C. Propranolol
D. Digoxin
Rationale: Propranolol undergoes extensive first-pass metabolism in the liver,
resulting in a low oral bioavailability. Lorazepam and digoxin have higher
bioavailabilities.
, Question 11. Which pharmacokinetic parameter measures the efficiency of drug
removal from the body?
A. Clearance
B. Volume of distribution
C. Half-life
D. Bioavailability
Rationale: Clearance (CL) is the volume of plasma cleared of drug per unit time. It
determines the maintenance dose required to achieve a target steady-state
concentration.
Question 12. A patient is given a drug that induces CYP3A4. What effect will this
have on a co-administered drug that is a substrate of CYP3A4?
A. Increased plasma concentration of the substrate drug
B. Decreased plasma concentration of the substrate drug
C. No effect on the substrate drug
D. Increased half-life of the substrate drug
Rationale: Enzyme inducers increase the metabolism of substrate drugs,
decreasing their plasma concentrations and potentially reducing their therapeutic
effect.
Question 13. Which of the following is a prodrug?
A. A drug that is active in its administered form
B. A drug that requires metabolic activation in the body to become
pharmacologically active
C. A drug that is excreted unchanged
D. A drug that inhibits its own metabolism
Rationale: A prodrug is an inactive compound that is metabolized in the body to
release the active drug (e.g., enalapril is a prodrug of enalaprilat).
Question 14. What is the therapeutic index of a drug?
A. The ratio of the dose required to produce a therapeutic effect to the dose that
produces a toxic effect
B. The ratio of the toxic dose to the therapeutic dose (TD50/ED50)
C. The time it takes to reach peak plasma concentration
D. The percentage of drug bound to plasma proteins
Rationale: The therapeutic index is the ratio of the dose that produces toxicity
(TD50) to the dose that produces the desired therapeutic effect (ED50). A larger
therapeutic index indicates a safer drug.
Midterm Comprehensive Examination
2026/2027 | Verified Questions
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles and Pharmacokinetics
Question 1. A patient with hepatic impairment is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic principle most
accurately guides dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30
mL/min
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral
bioavailability of high-extraction drugs. Therefore the dose must be decreased to
avoid toxicity. This principle is foundational in advanced pharmacokinetics for
nurse prescribers.
Question 2. Which parameter best predicts the time required for a drug to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Rationale: Steady state is reached after approximately four to five half-lives
regardless of dose or infusion rate. Elimination half-life is therefore the primary
determinant of time to steady state.
Question 3. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
,D. Decreased free fraction because hepatic synthesis of albumin increases
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of
highly protein-bound drugs. The unbound concentration drives pharmacologic
effect and toxicity risk, requiring careful monitoring.
Question 4. Which cytochrome P450 enzyme is responsible for the majority of
clinically significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
Rationale: CYP3A4 is involved in the metabolism of more than 50% of all
prescription medications. It is highly susceptible to inhibition and induction,
making it the most common source of clinically significant drug interactions.
Question 5. A patient is prescribed a drug with a narrow therapeutic index. Which
monitoring strategy is most appropriate?
A. Routine monitoring of serum drug levels to ensure they remain within the
therapeutic range
B. Administering the drug only when symptoms are severe
C. Using the standard dose without monitoring, as it is usually safe
D. Monitoring only for adverse effects, not serum levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Routine serum level monitoring is essential to prevent
toxicity or subtherapeutic failure.
Question 6. What is the primary purpose of a loading dose?
A. To maintain steady-state plasma concentrations
B. To rapidly achieve therapeutic plasma concentrations
C. To reduce the risk of adverse effects
D. To prolong the elimination half-life of the drug
Rationale: A loading dose is administered to rapidly reach the therapeutic range,
bypassing the time it would take to reach steady state through maintenance dosing
alone.
Question 7. Which of the following describes a drug that is a competitive
antagonist?
A. It binds to the receptor and activates it.
B. It binds to the receptor and blocks the action of an agonist, but can be
,overcome by increasing the agonist concentration.
C. It binds irreversibly to the receptor and permanently inactivates it.
D. It binds to an allosteric site and enhances the agonist effect.
Rationale: A competitive antagonist competes with the agonist for the same
binding site. Its effects can be overcome by increasing the concentration of the
agonist.
Question 8. A patient with renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What is the most appropriate initial dose
adjustment?
A. Decrease the dose or increase the dosing interval.
B. Increase the dose to compensate for loss of renal function.
C. Maintain the usual dose but monitor closely.
D. Administer a loading dose only.
Rationale: Renal impairment reduces the clearance of drugs excreted unchanged
by the kidneys, leading to accumulation and toxicity. Dose reduction or interval
extension is necessary.
Question 9. What is the definition of bioavailability?
A. The amount of drug metabolized by the liver
B. The fraction of an administered dose that reaches the systemic circulation
unchanged
C. The volume of plasma cleared of drug per unit time
D. The time it takes for half of the drug to be eliminated
Rationale: Bioavailability (F) represents the extent and rate at which the active
drug enters systemic circulation, which is 100% for intravenous administration but
less for oral routes due to incomplete absorption and first-pass metabolism.
Question 10. Which of the following is an example of a drug that undergoes
extensive first-pass metabolism?
A. Diazepam
B. Lorazepam
C. Propranolol
D. Digoxin
Rationale: Propranolol undergoes extensive first-pass metabolism in the liver,
resulting in a low oral bioavailability. Lorazepam and digoxin have higher
bioavailabilities.
, Question 11. Which pharmacokinetic parameter measures the efficiency of drug
removal from the body?
A. Clearance
B. Volume of distribution
C. Half-life
D. Bioavailability
Rationale: Clearance (CL) is the volume of plasma cleared of drug per unit time. It
determines the maintenance dose required to achieve a target steady-state
concentration.
Question 12. A patient is given a drug that induces CYP3A4. What effect will this
have on a co-administered drug that is a substrate of CYP3A4?
A. Increased plasma concentration of the substrate drug
B. Decreased plasma concentration of the substrate drug
C. No effect on the substrate drug
D. Increased half-life of the substrate drug
Rationale: Enzyme inducers increase the metabolism of substrate drugs,
decreasing their plasma concentrations and potentially reducing their therapeutic
effect.
Question 13. Which of the following is a prodrug?
A. A drug that is active in its administered form
B. A drug that requires metabolic activation in the body to become
pharmacologically active
C. A drug that is excreted unchanged
D. A drug that inhibits its own metabolism
Rationale: A prodrug is an inactive compound that is metabolized in the body to
release the active drug (e.g., enalapril is a prodrug of enalaprilat).
Question 14. What is the therapeutic index of a drug?
A. The ratio of the dose required to produce a therapeutic effect to the dose that
produces a toxic effect
B. The ratio of the toxic dose to the therapeutic dose (TD50/ED50)
C. The time it takes to reach peak plasma concentration
D. The percentage of drug bound to plasma proteins
Rationale: The therapeutic index is the ratio of the dose that produces toxicity
(TD50) to the dose that produces the desired therapeutic effect (ED50). A larger
therapeutic index indicates a safer drug.
